<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886507</url>
  </required_header>
  <id_info>
    <org_study_id>NIS 087-001</org_study_id>
    <nct_id>NCT02886507</nct_id>
  </id_info>
  <brief_title>Effects of NSK-SD (Nattokinase) on Blood Pressure</brief_title>
  <official_title>Effects of NSK-SD (Nattokinase) on Blood Pressure. A Randomized, Double-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Natural Immune Systems Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JBSL-USA Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Natural Immune Systems Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blinded placebo-controlled study to evaluate the effects of&#xD;
      NSK-SD consumption in subjects with Stage I hypertension.&#xD;
&#xD;
      The study population will be randomized into two groups, where both groups will receive&#xD;
      dietary and lifestyle recommendations to help reduce hypertension. One group will receive&#xD;
      placebo and the other group NSK-SD for 8 weeks.&#xD;
&#xD;
      The endpoint will be the change in systolic and diastolic blood pressure after 8 weeks of&#xD;
      treatment in the two subject groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous randomized double blinded placebo-controlled studies on the consumption of the&#xD;
      fibrinolytic enzyme Nattokinase and NSK-SD is transported across the gut, and has shown&#xD;
      multiple effects on vascular health, including fibrinolytic effects and regulation of blood&#xD;
      pressure.&#xD;
&#xD;
      A previous study on effects on blood pressure was conducted in an Asian population involving&#xD;
      86 people, where 73 people completed the study requirements (39 in the NSK-SD group, 34 in&#xD;
      the placebo group). The data showed statistically significant reduction in both systolic and&#xD;
      diastolic blood pressure after consumption of Nattokinase, whereas the changes after&#xD;
      consuming placebo were not significantly different from baseline.&#xD;
&#xD;
      The objective of this study is to evaluate the effects of consumption of nattokinase on&#xD;
      hypertension in a North American hypertensive population with associated genetic, dietary,&#xD;
      and lifestyle factors. This is in extension of, and contrast to, previous studies in Asian&#xD;
      populations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of hypertension</measure>
    <time_frame>Eight weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>von Willebrand factor</measure>
    <time_frame>Eight weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma renin activity</measure>
    <time_frame>Eight weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>NSK-SD (nattokinase)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One capsule (100 mg) nattokinase/day for the 8-week study duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One capsule placebo/day for the 8-week study duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>NSK-SD (nattokinase)</intervention_name>
    <description>Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.</description>
    <arm_group_label>NSK-SD (nattokinase)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo capsules contain microcrystalline cellulose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults of both genders;&#xD;
&#xD;
          -  Age 18-85 years;&#xD;
&#xD;
          -  Elevated blood pressure as identified by:&#xD;
&#xD;
               -  Systolic blood pressure 130mmHg or higher, or diastolic blood pressure 90mmHg or&#xD;
                  higher;&#xD;
&#xD;
               -  Confirmed on three separate occasions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of Nattokinase-containing supplements within 60 days prior to enrollment;&#xD;
&#xD;
          -  Currently on blood pressure medication;&#xD;
&#xD;
          -  History of cancer chemotherapy within the last 12 months;&#xD;
&#xD;
          -  Significant active uncontrolled disease (such as lymphoma, cirrhosis, nephritis,&#xD;
             uncompensated heart failure);&#xD;
&#xD;
          -  Consumption of more than an average of 2 standard alcoholic drinks/day (14 drinks per&#xD;
             week)&#xD;
&#xD;
          -  Currently experiencing intense stressful events/ life changes that would negatively&#xD;
             affect compliance;&#xD;
&#xD;
          -  Pregnant, nursing, or trying to become pregnant;&#xD;
&#xD;
          -  Women not using effective contraception;&#xD;
&#xD;
          -  Food allergies related to ingredients in test product.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gitte S Jensen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIS Labs</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Natural Immune Systems Inc</investigator_affiliation>
    <investigator_full_name>Gitte Jensen, Ph.D.</investigator_full_name>
    <investigator_title>Research director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Manuscript publication.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

